Actinium Pharmaceuticals Inc(ATNM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | 4.15 | EPS (ttm) | 0.36 | Insider Own | 1.76% | Shs Outstand | 31.4M | Perf Week | -2.63% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | -420.75% | Insider Trans | - | Shs Float | 30.9M | Perf Month | 28.7% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.24 | Inst Own | 16.82% | Short Float | 2.04% | Perf Quarter | 82.38% |
| Income | 0.01B | P/S | 1.33 | EPS this Y | 116.21% | Inst Trans | -0.11% | Short Ratio | 3.41 | Perf Half Y | 30.97% |
| Sales | 0.04B | P/B | 1.54 | EPS next 5Y | 20.23% | ROA | 21.92% | Short Interest | 0.63M | Perf YTD | 8.82% |
| Book/sh | 0.96 | P/C | 1.28 | EPS past 3/5Y | 7.39% 9.91% | ROE | 45.86% | 52W High | -13.95% ($1.72) | Perf Year | 4.23% |
| Cash/sh | 1.16 | P/FCF | - | Sales past 3/5Y | -54.09% - | ROIC | 36.6% | 52W Low | 101.33% ($0.74) | Perf 3Y | -73.43% |
| Dividend Est. | - | EV/EBITDA | 1.07 | EPS Y/Y TTM | 127.1% | Gross Margin | 96.97% | Volatility(W/M) | 10.48% 10.12% | Perf 5Y | -81.15% |
| Dividend TTM | - | EV/Sales | 0.33 | Sales Y/Y TTM | 11.11% | Oper. Margin | 27.23% | ATR (14) | 0.12 | Perf 10Y | -95.16% |
| Dividend Ex-Date | - | Quick Ratio | 4.08 | EPS Q/Q | 502.9% | Profit Margin | 32.23% | RSI (14) | 60.97 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.08 | Sales Q/Q | - | SMA20 | 17.39% ($1.26) | Beta | 0.33 | Target Price | $3.67 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/08/03 | SMA50 | 24.14% ($1.19) | Rel Volume | 0.85 | Prev Close | $1.53 |
| Employees | 25 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 545% - | SMA200 | 32.13% ($1.12) | Avg Volume(3M) | 0.18M | Price | $1.48 |
| IPO | 2011/6/2 | Option/Short | Yes/Yes | Trades | 283 | Volume | 157,412 | Change | -3.27% |
Actinium Pharmaceuticals is a clinical-stage biotech developing "antibody-radioconjugates (ARC)"—therapeutics that combine antibodies with radioactive isotopes. Its pipeline includes targeted conditioning for bone marrow transplantation, conditioning for CAR-T therapy, and a novel radiotherapy for prostate cancer.
Over the past 1 year, on the higher side
14% below its 1-year high.
Traded about as much as usual. That is 85% of its average volume.
ATNM makes money exceptionally well
Of every $100 in sales, $27.23 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +116.2% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $415. Peers typically go for $1,433.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -81.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 16.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #418 of 595 in the industry
Based on market cap of $47M.
IBIO#417 iBio Inc $47M PER - ATNM#418 Actinium Pharmaceuticals Inc $47M PER 4.2 
LONA#418 LeonaBio Inc $47M PER - 
IMA#418 ImageneBio Inc $47M PER - 
BMEA#421 Biomea Fusion Inc $46M PER - 
FAQ
What kind of company is ATNM?
ATNM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ATNM?
The market cap of ATNM is approximately $47M, ranking 4,870 within its sector.
What is the P/E ratio of ATNM?
ATNM has a P/E ratio of approximately 4.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ATNM?
ATNM has recorded a 52-week high of $1.72 and a low of $0.74.
